BlackThorn Therapeutics
BlackThorn Therapeutics develops precision medicines that target dysfunctional brain circuits to treat central nervous system and neurobehavioral disorders. The company applies advances in computational and clinical neuroscience through a proprietary computational platform to identify novel targets, small-molecule drug candidates, and biologically defined patient subgroups most likely to respond. It is a clinical-stage biopharmaceutical company combining neuroscience data, machine learning models, and biomarker-driven patient stratification. BlackThorn focuses on developing therapeutics for CNS indications and advancing candidates through clinical trials. Its approach positions the company to address unmet needs in neuropsychiatry by linking neuroscience-derived targets to precision drug development.
BlackThorn Therapeutics
BlackThorn Therapeutics develops precision medicines that target dysfunctional brain circuits to treat central nervous system and neurobehavioral disorders. The company applies advances in computational and clinical neuroscience through a proprietary computational platform to identify novel targets, small-molecule drug candidates, and biologically defined patient subgroups most likely to respond. It is a clinical-stage biopharmaceutical company combining neuroscience data, machine learning models, and biomarker-driven patient stratification. BlackThorn focuses on developing therapeutics for CNS indications and advancing candidates through clinical trials. Its approach positions the company to address unmet needs in neuropsychiatry by linking neuroscience-derived targets to precision drug development.